Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial.

ABSTRACT:

Objective

Women with pre-eclampsia have elevated circulating levels of soluble fms-like tyrosine kinase-1 (sFlt-1). Statins can reduce sFlt-1 from cultured cells and improve pregnancy outcome in animals with a pre-eclampsia-like syndrome. We investigated the effect of pravastatin on plasma sFlt-1 levels during pre-eclampsia.

Design

Blinded (clinician and participant), proof of principle, placebo-controlled trial.

Setting

Fifteen UK maternity units.

Population

We used a minimisation algorithm to assign 62 women with early-onset pre-eclampsia (24⁺⁰ -31⁺⁶  weeks of gestation) to receive pravastatin 40 mg daily (n = 30) or matched placebo (n = 32), from randomisation to childbirth.

Primary outcome

Difference in mean plasma sFlt-1 levels

SUBMITTER: Ahmed A 

PROVIDER: S-EPMC7063986 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature